《武田制药Takeda Pharmaceutical（TAK）2025财年第一季度财报「NYSE」（英文版）（71页）.pdf》由会员分享，可在线阅读，更多相关《武田制药Takeda Pharmaceutical（TAK）2025财年第一季度财报「NYSE」（英文版）（71页）.pdf（71页珍藏版）》请在三个皮匠报告上搜索。

1、Takeda Quarterly Financial ReportFor the Quarter Ended June 30,2025 Table of ContentsFinancial Highlights .3Selected Financial Results .3Revenue by Region .4Recent Developments .5Pipeline and R&D Activities .5Analysis of results of operations,financial position,and cash flow .9Results of Operations

2、.9Financial Position .15Cash Flows .17Forecast and Management Guidance .18Condensed Interim Consolidated Financial Statements .20(1)Condensed Interim Consolidated Statements of Profit or Loss .20(2)Condensed Interim Consolidated Statements of Comprehensive Income .21(3)Condensed Interim Consolidated

3、 Statements of Financial Position .22(4)Condensed Interim Consolidated Statements of Changes in Equity .24(5)Condensed Interim Consolidated Statements of Cash Flows .26(6)Other Information .28Supplementary Information .291.Pipeline .30I.Clinical Development Activities .30II.Recent Progress in stage

4、.38III.Projects removed from pipeline .39IV.Research&Development collaborations/partnering .402.Supplementary Revenue Information .45Revenue by region .45Year to date .45Quarterly .46Product Sales Analysis(vs PY Reported Actual).47Year to date .47Product Sales Analysis(Reported AER&Core CER Change).

5、49Product Forecast .51Financial Appendix .Financial HighlightsSelected Financial ResultsTakeda uses certain non-IFRS measures to supplement the analysis of results of operations under International Financial Reporting Standards(IFRS).Refer to Financial Appendix for the definition and reconciliations

6、 of non-IFRS Measures.Financial ResultsThree-month Period Ended June 30,AER*CER*(JPY millions)20242025JPY Change%Change%ChangeRevenue1,207,9901,106,685(101,306)(8.4)%(3.7)%Operating profit166,329184,56618,237 11.0%14.0%Profit before tax136,604150,63014,026 10.3%14.1%Net profit for the period95,29912